CRISPR Therapeutics (CRSP) has been back in focus after a series of reports highlighted strong investor interest, tied to expectations for higher revenue from its Casgevy gene therapy, even as the company continues to report losses.

The recent 16.9% 1 month share price return and 11.6% year to date share price return to around $60 suggest momentum has picked up again. The 1 year total shareholder return of 36.9% contrasts with a weaker 5 year total shareholder return of a 51.7% loss, as investors weigh Casgevy revenue expectations against continued losses and pipeline updates later in 2026.

If Casgevy has you thinking about where gene editing and AI might intersect in healthcare, it could be worth scanning 31 healthcare AI stocks as a starting list of ideas.

With CRISPR Therapeutics still reporting a US$581.6 million loss but trading at about US$60, with analysts’ average price target near US$84.78 and an indicated intrinsic discount of roughly 69%, is this a genuine opportunity, or is future growth already priced in?

Preferred Multiple of Price to Book: Is it justified?

At around $60 per share and a Price to Book ratio of 3x, CRISPR Therapeutics screens as more expensive than the wider US biotech group, but cheaper than its closer peer set.

P/B compares the market value of the company to the accounting value of its net assets, so it is often used for early stage or loss making businesses where earnings based metrics are less helpful. For a gene editing company with limited current revenue and sizeable losses, P/B gives you a quick sense of how much investors are paying for the balance sheet and the underlying platform.

Here, the picture is mixed. On one side, CRISPR Therapeutics looks expensive against the US biotechs industry average P/B of 2.6x, which suggests the broader sector trades at a lower premium to book value. On the other side, it screens as good value versus a peer average P/B of 16.5x, which implies its current multiple sits well below what similar names are trading at.

Result: Price to Book ratio of 3x (ABOUT RIGHT)

However, you still have to weigh the US$581.6 million loss and very limited US$3.51 million revenue, as well as the risk that pipeline or Casgevy updates disappoint.

Another View: What Our DCF Model Suggests

If P/B leaves you on the fence, our DCF model offers a very different angle. On that measure, CRISPR Therapeutics at about $60 is assessed as trading below an estimated future cash flow value of $190.73, which points to a large potential valuation gap. Could the market be underestimating what Casgevy and the wider pipeline might be worth in the long term, or are the loss profile and execution risks doing the heavy lifting here?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CRISPR Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the mix of enthusiasm and caution here matches your own read on CRISPR Therapeutics? Take a closer look at the numbers, weigh the trade offs for yourself, and then check the 2 key rewards and 2 important warning signs to see how other investors are framing both sides of the story.

Looking for more investment ideas?

If CRISPR Therapeutics has sparked your curiosity, do not stop here. Put that momentum to work by lining up your next set of high conviction watchlist candidates.

• Spot potential value opportunities early by scanning our 47 high quality undervalued stocks, which pairs solid fundamentals with pricing that may not fully reflect them yet.
• Lock in a focus on income by reviewing 14 dividend fortresses, a list of companies offering 5%+ yields with an emphasis on resilience.
• Aim for staying power by checking 77 resilient stocks with low risk scores, highlighting businesses that score well on balance sheet strength and risk factors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.